• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long ‐Term Extension Studies of Tofacitinib in Patients with Rheumatoid Arthritis
ConclusionIn this post ‐hoc analysis, after 24 weeks of tofacitinib, increased HDL‐c, but not increases in LDL‐c or TC, appeared to be associated with lower future MACE risk. Further data are needed to test the cardiovascular safety of tofacitinib.This article is protected by copyright. All rights reserved.
Source: Arthritis and Rheumatology - April 16, 2019 Category: Rheumatology Authors: Christina Charles ‐Schoeman, Ryan DeMasi, Hernan Valdez, Koshika Soma, Lie‐Ju Hwang, Mary G. Boy, Pinaki Biswas, Iain B. McInnes Tags: Full Length Source Type: research

Trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis (TRACE RA): A multicenter, randomized, placebo controlled trial
ConclusionAtorvastatin 40mg daily was safe and resulted in significantly greater reduction of LDLc than placebo in patients with RA. The 40% (adjusted) CVE risk reduction is consistent with the Cholesterol Treatment Trialists ’ Collaboration meta‐analysis of statin effects in other populations.This article is protected by copyright. All rights reserved.
Source: Arthritis and Rheumatology - April 14, 2019 Category: Rheumatology Authors: George D. Kitas, Peter Nightingale, Jane Armitage, Naveed Sattar, Jill J.F. Belch, Deborah P.M. Symmons, The TRACE RA consortium, George Kitas, Jill Belch, Deborah Symmons, Hawys Williams, Shobna Vasishta, Rebecca Storey, Peter Nightingale, Tags: Full Length Source Type: research

Ibudilast Inhibits Chemokine Expression in Rheumatoid Arthritis Synovial Fibroblasts and Exhibits Immunomodulatory Activity in Experimental Arthritis
ConclusionOur findings indicate that ibudilast reduces the expression and/or secretion of inflammatory mediators from activated human leukocytes and RASFs, inhibits Th17 cell responses in vivo, and improves established arthritis. Given the established safety profile of ibudilast in humans, its clinical evaluation in RA, either alone or in combination with a TNF inhibitor, should be considered.
Source: Arthritis and Rheumatology - April 11, 2019 Category: Rheumatology Authors: Felix I. L. Clanchy, Richard O. Williams Tags: Original Article Source Type: research

Reduced right ventricular output reserve in patients with systemic sclerosis and mildly elevated pulmonary arterial pressures
ConclusionThe results of this study suggest that impaired 6MWD in SSc ‐patients with mildly elevated mPAP might be caused by reduced PAC during exercise and reduced RV output reserve, presumably due to impaired coupling between the right ventricle and the pulmonary vasculature. These findings give further evidence for the clinical relevance of mildly elevated mPAP i n patients with SSc.This article is protected by copyright. All rights reserved.
Source: Arthritis and Rheumatology - January 7, 2019 Category: Rheumatology Authors: Christian Nagel, Alberto M. Marra, Nicola Benjamin, Norbert Blank, Antonio Cittadini, Gerry Coghlan, Oliver Distler, Christopher P Denton, Benjamin Egenlauf, Christoph Fiehn, Christine Fischer, Satenik Harutyunova, Marius M Hoeper, Hanns ‐M Tags: Full Length Source Type: research

Ibudilast inhibits chemokine expression in rheumatoid synovial fibroblasts and exhibits immunomodulatory activity in experimental arthritis
ConclusionIbudilast reduced the expression and/or secretion of inflammatory mediators from activated human leukocytes and RASF, inhibited Th17 responses in vivo and improved established arthritis. Given the established safety profile of ibudilast in man, its clinical evaluation in RA, either alone or in combination with a TNF inhibitor, should be considered.This article is protected by copyright. All rights reserved.
Source: Arthritis and Rheumatology - November 26, 2018 Category: Rheumatology Authors: Felix I.L. Clanchy, Richard O. Williams Tags: Full Length Source Type: research

Pages: 1  2